Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer

Aso, Mari; Toi, Yukihiro; Sugisaka, Jun; Aiba, Tomoiki; Kawana, Sachiko; Saito, Ryoichi; Ogasawara, Takahiro; Tsurumi, Kyoji; Ono, Kana; Shimizu, Hisashi; Domeki, Yutaka; Terayama, Keisuke; Kawashima, Yosuke; Nakamura, Atsushi; Yamanda, Shinsuke; Kimura, Yuichiro; Honda, Yoshihiro; Sugawara, Shunichi

doi:10.1634/theoncologist.2019-0550

Cited by 42 publications

(46 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present large-scale study involving 280 patients, we evaluated the association between irAEs and therapeutic effects, searched for predictive factors for the onset of irAEs and examined whether irAE profiles differ among cancer types. In this study, the overall incidence of treatment-associated adverse events was 41.1%, which was comparable with the previously reported incidence [5,8,9,12]. The most common adverse events were skin disorders.…”

Section: Discussionsupporting

confidence: 89%

“…irAEs attracted attention soon after the approval of ICIs, and since then, several reports have been published [5][6][7]. Although symptoms such as type 1 diabetes mellitus and severe diarrhoea had attracted attention, recent reports have indicated that the onset of irAEs contributes to the prognosis of patients [8][9][10][11][12][13]. However, many of the reports describe studies on malignant melanoma and lung cancer, for which ICIs were used ahead of the use for other cancers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

et al. 2020

View full text Add to dashboard Cite

Background: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) are used for the treatment of various cancer types. However, immune-related adverse events (irAEs) occur in patients treated with ICIs. Several small-scale studies have reported the onset of irAEs and therapeutic effects of ICIs. Here we report a large-scale retrospective study covering a wide range of cancers. We evaluated irAEs and the therapeutic effects of ICIs and determined whether irAEs could be predicted.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To account for the presence of lead-time bias associated with the time-dependent development of irAEs, we selected a 6-weeks study period in accordance with that in previous studies 10 , 11 . Another reason why the 6-week period was chosen was the occurrence rate of irAEs and the timing of computerized tomography.…”

Section: Discussionmentioning

confidence: 99%

Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study

Egami¹,

Kawazoe²,

Hashimoto³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Background: Pembrolizumab is currently the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). However, the association between immune-related adverse events (irAEs) and peripheral blood cell counts remains unclear. We aimed at identifying peripheral blood cell counts that may predict the development of pembrolizumab-induced irAEs. Methods: We retrospectively analyzed data on consecutive patients with advanced NSCLC who received pembrolizumab monotherapy as first-line or later-line therapy at the National Cancer Center Hospital and Keio University Hospital. We used data between December 2015 and November 2018. The primary endpoint was the relationship between peripheral blood cell count data and early-onset irAEs during the 6-weeks study period. Receiver operating characteristic (ROC) curve and multivariable logistic regression analyses were performed. Results: In total, 92 patients were evaluated, of whom 45 (48.9%) had at least one irAE during the first 6-weeks after treatment initiation. The ROC curves revealed that the optimal cutoff of pretreatment absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) for onset of irAEs were 1459, 2.320, 1.538, and 165, respectively. Multivariable logistic regression analyses revealed that pretreatment ALC>1450 and LMR>1.6 were significantly associated with a reduced risk for onset of any irAEs, whereas pretreatment NLR>2.3 and PLR>165 were significantly associated with an increased risk. Conclusions: The findings suggest that considering the routine availability of blood cell count data before the initiation of treatment with pembrolizumab, it may be useful in identifying early-onset irAEs during the 6-weeks study period in clinical practice.

show abstract

“…Several studies have shown that the presence of irAEs is associated with a higher efficacy and improved overall survival in several solid tumors treated with ICIs, including NSCLC ( 16 – 18 ). Nonetheless, ICIP might be an exemption to this rule.…”

Section: Discussionmentioning

confidence: 99%

Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy

et al. 2020

View full text Add to dashboard Cite

Introduction: Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially life threatening immune-related adverse event (irAE), especially in non-small cell lung cancer (NSCLC) patients. Currently, the potential for increased irAE in patients who receive radiotherapy is scarcely known, although a connection between antitumor immune responses and irAEs has been suggested. In this study, we evaluated the development of ICIP in non-small cell lung cancer patients with prior radiotherapy, treated with immunotherapy in the second-line. Methods: In this retrospective trial, we included patients treated with second-line immunotherapy at the National Cancer Institute in Mexico City from February 2015 to February 2018. Clinical, radiological and treatment variables were evaluated according to the presence of ICIP as defined by the Common Terminology Criteria for Adverse Events (4.0) in patients with or without a previous (≥months) history of radiotherapy. Results: Among 101 NSCLC patients who received treatment with ICIs, 22 patients (21.8%) were diagnosed with ICIP, of which 73% (16/22) had a history of radiotherapy (OR 6.04, 95% CI 2.03−18.0, p < 0.001). Median progression free survival and overall survival were similar in patients who developed ICIP compared with those who did not, however, patients who presented grade ≥ 2 ICIP had an increased risk of mortality (HR 2.54, 95% CI 1.20−5.34, p = 0.014). Conclusion: In this real-world cohort of NSCLC patients treated with ICI, the history of prior radiotherapy was associated with increased risk for ICIP development. Unlike other irAEs, grade ≥ 2 ICIP is an independent prognostic factor for decreased survival in NSCLC patients.

show abstract

Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer

Cited by 42 publications

References 38 publications

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study

Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy

Contact Info

Product

Resources

About